Evidence map›Paper›PMID 42538409›Full record

ArticleOncogene2026

The establishment of prostate-specific, SKP2 humanized mice by CRISPR knock-in method reveals neoplastic initiation and microenvironmental reprogramming.

Liankun Song, Yurong Song, Vyvyan Nguyen, Shan Xu, Kelly Ho, Altaf Mohammed, Robert H Shoemaker, Bang H Hoang, Jianhua Yu, Edward Uchio and 1 more

Abstract read
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Liankun SongDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Yurong SongVaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-7151-0575
Vyvyan NguyenDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Shan XuDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Kelly HoDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Altaf MohammedDivision of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.
Robert H ShoemakerDivision of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.ORCID http://orcid.org/0000-0003-3608-1714
Bang H HoangDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0002-2950-3221
Jianhua YuChao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA.
Edward UchioDepartment of Urology, University of California, Irvine, Orange, CA, USA.
Xiaolin ZiDepartment of Urology, University of California, Irvine, Orange, CA, USA. xzi@hs.uci.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancerR01CA260351 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Anshu Agrawal, Xiaolin Zi · 2022 to 2026
$1.8M
Leveraging Tumor Suppressor Inactivation for Osteosarcoma TherapyR01CA255643 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HOANG, BANG H · 2021 to 2024
$1.7M
Nautral products for targeting Skp2 in cancer interceptionUG3CA290368 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Xiaolin Zi · 2024 to 2026
$1.0M
BLRD VA I01 BX005105NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA255643NCI NIH HHS R01 CA260351NCI NIH HHS UG3 CA290368NIH HHS 75N91019D00024U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA255643U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01 CA260351U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) UG3 CA290368U.S. Department of Veterans Affairs (Department of Veterans Affairs) I01BX005105
6 · The paper itself

Abstract

Genetic inactivation of SKP2 has been shown to effectively prevent cancer initiation and block tumorigenesis. However, direct in vivo evidence for SKP2 on cancer initiation and prostatic microenvironment is still lacking and a SKP2 humanized mouse model is critical for developing prostate cancer immunoprevention approaches through targeting SKP2. We therefore have established a prostate-specific human SKP2 knock-in mouse model driven by an endogenous mouse probasin promoter. Overexpression of hSKP2 induces PIN and low-grade carcinoma. RNA-sequencing analysis revealed significant gene expression alterations in EMT, extracellular matrix, and interferon signaling. Single-cell deconvolution showed an increase of fibroblast population and a decrease of CD8

Indexed as

CarcinogenesisProstatic NeoplasmsS-Phase Kinase-Associated ProteinsTumor MicroenvironmentAnimalsCell MovementCell Transformation, NeoplasticCRISPR-Cas SystemsDisease Models, AnimalEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGene Knock-In TechniquesHumansMaleMiceMice, TransgenicSKP2 protein, humanS-Phase Kinase-Associated Proteins

Identifiers

PMID42538409
PMCPMC13549951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.